Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Brian I. Rini, Yoshihiko Tomita, Bohuslav Melichar, Takeshi Ueda, Viktor Grünwald, Mayer N. Fishman, Hirotsugu Uemura, Mototsugu Oya, Angel H. Bair, Glen I. Andrews, Brad Rosbrook, Eric Jonasch

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)

Abstract

In a randomized phase II trial in treatment-naive patients with metastatic renal cell carcinoma, axitinib dose titration was associated with significantly higher objective response rate compared with placebo dose titration. In this updated analysis, median overall survival was numerically longer with axitinib versus placebo titration (42.7 vs. 30.4 months). No new safety concerns were observed after long-term axitinib treatment. Background In a randomized phase II trial in metastatic renal cell carcinoma (mRCC), objective response rate was significantly higher with axitinib versus placebo titration (54% vs. 34%; 1-sided P = .019). Patients and Methods Treatment-naive patients with mRCC (n = 213) received axitinib 5 mg twice per day (b.i.d.) for 4 weeks. Patients meeting dose titration criteria were randomized to receive axitinib 5 mg b.i.d. with axitinib or placebo titration (n = 56 each); 91 patients ineligible for randomization continued axitinib 5 mg b.i.d.; 10 discontinued before randomization. Results Median overall survival (95% confidence interval [CI]) was 42.7 months (24.7-not estimable) with axitinib titration versus 30.4 months (23.7-45.0) with placebo titration (stratified hazard ratio, 0.785; 95% CI, 0.485-1.272; 1-sided P = .162), and 41.6 months (95% CI, 33.0-not estimable) in nonrandomized patients. Safety data were consistent with previous reports. Conclusion Median overall survival was numerically longer in patients with first-line mRCC who received axitinib versus placebo titration. No new safety signal was observed after long-term axitinib treatment in first-line mRCC.

Original languageEnglish
Pages (from-to)499-503
Number of pages5
JournalClinical Genitourinary Cancer
Volume14
Issue number6
DOIs
Publication statusPublished - 2016 Dec 1

Keywords

  • First-line treatment
  • Kidney cancer
  • Phase II
  • VEGFR inhibitor
  • mRCC

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this